氟替美维吸入粉雾剂联合小剂量阿奇霉素用于老年AECOPD患者肺康复治疗中的临床观察  

Clinical Observation of Flutemevir Powder Inhalation Combined with Low-dose Azithromycin for Pulmonary Rehabilitation Treatment in Elderly Patients with AECOPD

作　　者：刘平香[1] 董利民[1] 沈湘波[1] LIU Pingxiang;DONG Limin;SHEN Xiangbo(Department of Respiration,Pingxiang People's Hospital,Pingxiang 337000,China;不详)

机构地区：[1]萍乡市人民医院呼吸科,江西萍乡337000

出　　处：《中国医学创新》2024年第9期129-133,共5页Medical Innovation of China

基　　金：萍乡市科技计划项目(2020PY010)。

摘　　要：目的:探究氟替美维吸入粉雾剂联合小剂量阿奇霉素对老年慢性阻塞性肺疾病急性加重期(acute exacerbation chronic obstructive pulmonary disease,AECOPD)患者肺康复治疗的临床效果。方法:于2021年1月—2023年6月萍乡市人民医院呼吸科收治的老年AECOPD患者中选取80例为研究对象,并按随机数字表法分成对照组(40例)和研究组(40例)。两组均于病情稳定后给予治疗,对照组给予氟替美维吸入粉雾剂治疗,研究组加用小剂量阿奇霉素治疗,均治疗1个月。比较两组炎症指标[C反应蛋白(C reactive protein,CRP)、白细胞介素-6(interleukin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-alpha,TNF-α)]、肺功能情况[第1秒用力呼气容积(forced exhalation volume for1 second,FEV1)、用力肺活量(forced vital capacity,FVC)、FEV1/FVC%]、慢阻肺自我评估测试(COPD assessment test,CAT)评分、圣乔治呼吸问卷(St.George's respiratory questionnaire,SGRQ)评分和不良反应发生率的差异。结果:治疗后,两组的CRP、IL-6、TNF-α水平均低于治疗前,FEV1、FVC、FEV1/FVC%水平均高于治疗前,且研究组炎症指标和肺功能情况的改善程度均优于对照组,差异均有统计学意义(P<0.05)。治疗后,两组CAT、SGRQ各项评分均低于治疗前,且研究组均低于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论:氟替美维吸入粉雾剂联合小剂量阿奇霉素对老年AECOPD患者肺康复的治疗效果显著,能有效降低炎症指标水平,改善肺功能情况和呼吸症状,提高生活质量。Objective:To explore the clinical effect of Flutemevir Powder Inhalation combined with low-dose Azithromycin for pulmonary rehabilitation treatment in elderly patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Method:A total of 80 elderly patients with AECOPD admitted to Respiratory Department of Pingxiang People's Hospital were enrolled as the research objects from January 2021 to June 2023,they were divided into control group(40 cases)and study group(40 cases)by random number table method.Both groups received treatment after their condition stabilized.Control group was given Flutemevir Powder Inhalation,while study group was additionally given low-dose Azithromycin.All were treated for 1 month.The inflammatory indexes[C reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-alpha(TNF-α)],pulmonary function[forced exhalation volume for 1 second(FEV1),forced vital capacity(FVC),FEV1/FVC%],scores of COPD assessment test(CAT)and St.George's respiratory questionnaire(SGRQ)and incidence of adverse reactions were compared between the two groups.Result:After treatment,levels of CRP,IL-6 and TNF-αwere decreased,while levels of FEV1,FVC and FEV1/FVC%were increased in both groups,and the improvement of inflammatory indexes and pulmonary function in study group were better than those in the control group(P<0.05).After treatment,scores of CAT and SGRQ in both groups were decreased,those in study group were lower than those in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The application effect of Flutemevir Powder Inhalation combined with low-dose Azithromycin is significant in pulmonary rehabilitation treatment of elderly patients with AECOPD,which can effectively reduce levels of inflammatory indexes,improve pulmonary function,respiratory symptoms and quality of life.

关 键 词：氟替美维吸入粉雾剂 阿奇霉素 老年 急性加重期 慢性阻塞性肺疾病 肺康复 

分 类 号：R563.9[医药卫生—呼吸系统]